Literature DB >> 22683512

C-terminal Agrin Fragment as a potential marker for sarcopenia caused by degeneration of the neuromuscular junction.

M Drey1, C C Sieber, J M Bauer, W Uter, P Dahinden, R G Fariello, J W Vrijbloed.   

Abstract

INTRODUCTION: Sarcopenia is considered to be an enormous burden for both the individuals affected and for society at large. A multifactorial aetiology of this geriatric syndrome has been discussed. Amongst other pathomechanisms, the degeneration of the neuromuscular junction (NMJ) may be of major relevance. The intact balance between the pro-synaptic agent agrin and the anti-synaptic agent neurotrypsin ensures a structurally and functionally intact NMJ. Excessive cleavage of the native motoneuron-derived agrin by neurotrypsin into a C-terminal Agrin Fragment (CAF) leads to functional disintegration at the NMJ and may consecutively cause sarcopenia. The present study evaluates the hypothesis that CAF serum concentration is a potential marker for the loss of appendicular lean mass in older adults. It also explores how CAF concentration is influenced by vitamin D supplementation and physical exercise.
METHOD: Serum was taken from 69 (47 female) prefrail community-dwelling older adults participating in a training intervention study to measure the CAF concentration using the Western blot technique. All participants were supplemented orally with vitamin D3 before the training intervention period commenced. Appendicular lean mass (aLM) was evaluated by dual energy X-ray absorptiometry. Multiple linear regression models were used to identify factors significantly associated with CAF concentration.
RESULTS: Appendicular lean mass, age and sex were identified as significant explanatory factors for CAF concentration. Gait speed and hand grip strength were not associated with CAF concentration. Male participants showed a strong correlation (r=-0.524) between CAF serum concentration and aLM, whereas this was not the case (r=-0.219) in females. Vitamin D supplementation and physical exercise were significantly associated with a reduction in CAF concentration, especially in participants with initially high CAF concentrations.
CONCLUSIONS: C-terminal Agrin Fragment could be a potential marker for identifying sarcopenia in a subgroup of affected individuals in the future. The decline of muscle mass seems to be a CAF-associated process in males, whereas the situation in females may be more complex and multifactorial. CAF concentration is reduced by vitamin D supplementation and physical exercise and therefore suggests a potentially positive effect on NMJs. Further prospective studies of sarcopenic patients in addition to muscle biopsy and electromyographical investigations are planned to verify the external validity of the CAF concept.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22683512     DOI: 10.1016/j.exger.2012.05.021

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN: 0531-5565            Impact factor:   4.032


  31 in total

Review 1.  Aspects of physical medicine and rehabilitation in the treatment of deconditioned patients in the acute care setting: the role of skeletal muscle.

Authors:  Michael Quittan
Journal:  Wien Med Wochenschr       Date:  2016-01-12

2.  Deletion of Pofut1 in Mouse Skeletal Myofibers Induces Muscle Aging-Related Phenotypes in cis and in trans.

Authors:  Deborah A Zygmunt; Neha Singhal; Mi-Lyang Kim; Megan L Cramer; Kelly E Crowe; Rui Xu; Ying Jia; Jessica Adair; Isabel Martinez-Pena Y Valenzuela; Mohammed Akaaboune; Peter White; Paulus M Janssen; Paul T Martin
Journal:  Mol Cell Biol       Date:  2017-05-02       Impact factor: 4.272

3.  The Reference Intervals for Serum C-Terminal Agrin Fragment in Healthy Individuals and as a Biomarker for Renal Function in Kidney Transplant Recipients.

Authors:  Dan Yu; Hai-Xia Li; Yi Liu; Ze-Wei Ying; Jing-Jing Guo; Chen-Ying Cao; Jia Wang; Yuan-Fang Li; Hui-Rong Yang
Journal:  J Clin Lab Anal       Date:  2016-09-17       Impact factor: 2.352

4.  Comprehensive geriatric assessment in the older cancer patient: coming of age in clinical cancer care.

Authors:  Cynthia Owusu; Nathan A Berger
Journal:  Clin Pract (Lond)       Date:  2014

Review 5.  Muscle quality in aging: a multi-dimensional approach to muscle functioning with applications for treatment.

Authors:  Maren S Fragala; Anne M Kenny; George A Kuchel
Journal:  Sports Med       Date:  2015-05       Impact factor: 11.136

6.  Effects of a One-Year Physical Activity Program on Serum C-Terminal Agrin Fragment (CAF) Concentrations among Mobility-Limited Older Adults.

Authors:  I Bondoc; S K Cochrane; T S Church; P Dahinden; S Hettwer; F-C Hsu; R S Stafford; M Pahor; T W Buford
Journal:  J Nutr Health Aging       Date:  2015-11       Impact factor: 4.075

7.  [Sarcopenia and frailty in neurology].

Authors:  W Maetzler; M Drey; A H Jacobs
Journal:  Nervenarzt       Date:  2015-04       Impact factor: 1.214

8.  Transient systemic mtDNA damage leads to muscle wasting by reducing the satellite cell pool.

Authors:  Xiao Wang; Alicia M Pickrell; Susana G Rossi; Milena Pinto; Lloye M Dillon; Aline Hida; Richard L Rotundo; Carlos T Moraes
Journal:  Hum Mol Genet       Date:  2013-06-10       Impact factor: 6.150

9.  Identification of biomarkers for physical frailty and sarcopenia through a new multi-marker approach: results from the BIOSPHERE study.

Authors:  Riccardo Calvani; Anna Picca; Federico Marini; Alessandra Biancolillo; Jacopo Gervasoni; Silvia Persichilli; Aniello Primiano; Hélio J Coelho-Junior; Matteo Cesari; Maurizio Bossola; Andrea Urbani; Graziano Onder; Francesco Landi; Roberto Bernabei; Emanuele Marzetti
Journal:  Geroscience       Date:  2020-06-01       Impact factor: 7.713

10.  Designing pharmaceutical trials for sarcopenia in frail older adults: EU/US Task Force recommendations.

Authors:  B Vellas; M Pahor; T Manini; D Rooks; J M Guralnik; J Morley; S Studenski; W Evans; C Asbrand; R Fariello; S Pereira; Y Rolland; G Abellan van Kan; M Cesari; Wm C Chumlea; R Fielding
Journal:  J Nutr Health Aging       Date:  2013-07       Impact factor: 4.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.